After a historic sell-off with stocks plummeting by more than 50 percent, can biotech bounce back? What might be driving this disinvestment despite increased new drug approvals by the FDA and generally higher interest in the sector? Is the disinvestment a result of the increased focus on platform technologies and trends such as artificial intelligence? These may be short-term setbacks, so what does the near future look like for this critical sector? Will innovation continue to drive growth? Where are the areas of greatest opportunity and unmet need?